S&P 500   4,563.04 (-0.69%)
DOW   36,128.29 (-0.32%)
QQQ   384.02 (-1.52%)
AAPL   188.02 (-1.68%)
MSFT   366.05 (-2.26%)
META   316.58 (-2.54%)
GOOGL   128.34 (-2.67%)
AMZN   144.27 (-1.88%)
TSLA   235.84 (-1.25%)
NVDA   451.89 (-3.37%)
NIO   7.27 (+1.68%)
BABA   73.06 (-1.26%)
AMD   117.66 (-3.07%)
T   16.63 (-0.78%)
F   10.75 (+1.61%)
MU   74.04 (-2.49%)
CGC   0.69 (+11.10%)
GE   121.54 (-0.78%)
DIS   91.94 (-0.69%)
AMC   7.03 (+2.48%)
PFE   29.43 (+1.80%)
PYPL   59.56 (-0.15%)
XOM   102.41 (-0.56%)
S&P 500   4,563.04 (-0.69%)
DOW   36,128.29 (-0.32%)
QQQ   384.02 (-1.52%)
AAPL   188.02 (-1.68%)
MSFT   366.05 (-2.26%)
META   316.58 (-2.54%)
GOOGL   128.34 (-2.67%)
AMZN   144.27 (-1.88%)
TSLA   235.84 (-1.25%)
NVDA   451.89 (-3.37%)
NIO   7.27 (+1.68%)
BABA   73.06 (-1.26%)
AMD   117.66 (-3.07%)
T   16.63 (-0.78%)
F   10.75 (+1.61%)
MU   74.04 (-2.49%)
CGC   0.69 (+11.10%)
GE   121.54 (-0.78%)
DIS   91.94 (-0.69%)
AMC   7.03 (+2.48%)
PFE   29.43 (+1.80%)
PYPL   59.56 (-0.15%)
XOM   102.41 (-0.56%)
S&P 500   4,563.04 (-0.69%)
DOW   36,128.29 (-0.32%)
QQQ   384.02 (-1.52%)
AAPL   188.02 (-1.68%)
MSFT   366.05 (-2.26%)
META   316.58 (-2.54%)
GOOGL   128.34 (-2.67%)
AMZN   144.27 (-1.88%)
TSLA   235.84 (-1.25%)
NVDA   451.89 (-3.37%)
NIO   7.27 (+1.68%)
BABA   73.06 (-1.26%)
AMD   117.66 (-3.07%)
T   16.63 (-0.78%)
F   10.75 (+1.61%)
MU   74.04 (-2.49%)
CGC   0.69 (+11.10%)
GE   121.54 (-0.78%)
DIS   91.94 (-0.69%)
AMC   7.03 (+2.48%)
PFE   29.43 (+1.80%)
PYPL   59.56 (-0.15%)
XOM   102.41 (-0.56%)
S&P 500   4,563.04 (-0.69%)
DOW   36,128.29 (-0.32%)
QQQ   384.02 (-1.52%)
AAPL   188.02 (-1.68%)
MSFT   366.05 (-2.26%)
META   316.58 (-2.54%)
GOOGL   128.34 (-2.67%)
AMZN   144.27 (-1.88%)
TSLA   235.84 (-1.25%)
NVDA   451.89 (-3.37%)
NIO   7.27 (+1.68%)
BABA   73.06 (-1.26%)
AMD   117.66 (-3.07%)
T   16.63 (-0.78%)
F   10.75 (+1.61%)
MU   74.04 (-2.49%)
CGC   0.69 (+11.10%)
GE   121.54 (-0.78%)
DIS   91.94 (-0.69%)
AMC   7.03 (+2.48%)
PFE   29.43 (+1.80%)
PYPL   59.56 (-0.15%)
XOM   102.41 (-0.56%)

Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO)

$0.20
+0.01 (+5.32%)
(As of 11:40 AM ET)
Compare
Today's Range
$0.19
$0.20
50-Day Range
$0.18
$0.38
52-Week Range
$0.15
$7.20
Volume
148,221 shs
Average Volume
253,138 shs
Market Capitalization
$3.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aptevo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Aptevo Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.78) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars


APVO stock logo

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

APVO Stock News Headlines

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com
Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
Aptevo Therapeutics GAAP EPS of -$0.50
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Aptevo to Present at Bio-Europe Conference
Aptevo Therapeutics Inc
APVO - Aptevo Therapeutics Inc.
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
45
Year Founded
2016

Profitability

Net Income
$8.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.11 million
Book Value
$0.84 per share

Miscellaneous

Free Float
16,965,000
Market Cap
$3.35 million
Optionable
Not Optionable
Beta
4.94

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Marvin L. White (Age 61)
    President, CEO & Director
    Comp: $892.86k
  • Mr. Jeffrey G. Lamothe CA (Age 57)
    Executive VP & COO
    Comp: $691.37k
  • Ms. SoYoung Kwon J.D.
    LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
  • Ms. Daphne L. Taylor (Age 57)
    Senior VP & CFO
  • Dr. Jane A. Gross Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $515.17k
  • Dr. Dirk Huebner M.D. (Age 60)
    Chief Medical Officer














APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings
or view top-rated stocks.

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO shares have decreased by 91.4% and is now trading at $0.20.
View the best growth stocks for 2023 here
.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 26,900 shares, a drop of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the days-to-cover ratio is presently 0.1 days.
View Aptevo Therapeutics' Short Interest
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.14.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (11.58%), Armistice Capital LLC (10.72%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -